FBC
GMAB icon

Fairfield, Bush & Co’s Genmab GMAB Stock Holding History

Fairfield, Bush & Co’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-30
Closed -$955 – 244
2023
Q4 		$955 Buy
+30
New +$942 ﹤0.01% 438
2023
Q3 		– Sell
-30
Closed -$1.14K – 253
2023
Q2 		$1.14K Buy
+30
New +$1.2K ﹤0.01% 452

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fairfield, Bush & Co's GMAB Position: Q1 2024 in Review

Fairfield, Bush & Co sold out of Genmab (GMAB) in Q1 2024, closing a stake of 30 shares — an estimated $955 sold.

Fairfield, Bush & Co first reported a position in GMAB in Q2 2023 and held it in 2 quarters. The position peaked at $1.14K in Q2 2023. 227 funds tracked by Wall St. Rank hold GMAB as of Q1 2024.

  • Fairfield, Bush & Co reported no remaining Genmab position as of Q1 2024 after selling out during the quarter.
  • Fairfield, Bush & Co sold 30 Genmab shares in Q1 2024, an estimated $955.
  • Fairfield, Bush & Co first reported a position in Genmab in Q2 2023 and held it in 2 quarters.
  • Fairfield, Bush & Co's Genmab position peaked at $1.14K in Q2 2023.
  • 227 funds tracked by Wall St. Rank held Genmab as of Q1 2024.

Based on Fairfield, Bush & Co's 13F filing for Q1 2024, filed 15 May 2024.